DK1206281T3 - Formulering indeholdende moxifloxacin og natriumchlorid - Google Patents

Formulering indeholdende moxifloxacin og natriumchlorid

Info

Publication number
DK1206281T3
DK1206281T3 DK00947994T DK00947994T DK1206281T3 DK 1206281 T3 DK1206281 T3 DK 1206281T3 DK 00947994 T DK00947994 T DK 00947994T DK 00947994 T DK00947994 T DK 00947994T DK 1206281 T3 DK1206281 T3 DK 1206281T3
Authority
DK
Denmark
Prior art keywords
sodium chloride
formulation containing
containing moxifloxacin
moxifloxacin
formulation
Prior art date
Application number
DK00947994T
Other languages
Danish (da)
English (en)
Inventor
Bernd Kuehn
Hans-Friedrich Mahler
Michael Eisele
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7917417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1206281(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of DK1206281T3 publication Critical patent/DK1206281T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00947994T 1999-08-06 2000-07-25 Formulering indeholdende moxifloxacin og natriumchlorid DK1206281T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19937116A DE19937116A1 (de) 1999-08-06 1999-08-06 Moxifloxacin Kochsalzformulierung
PCT/EP2000/007098 WO2001010465A1 (fr) 1999-08-06 2000-07-25 Composition de sel de cuisine a base de moxifloxacine
EP00947994A EP1206281B1 (fr) 1999-08-06 2000-07-25 Formulation comprenant moxifloxacin et chlorure de sodium

Publications (1)

Publication Number Publication Date
DK1206281T3 true DK1206281T3 (da) 2004-10-25

Family

ID=7917417

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00947994T DK1206281T3 (da) 1999-08-06 2000-07-25 Formulering indeholdende moxifloxacin og natriumchlorid

Country Status (40)

Country Link
US (1) US6548079B1 (fr)
EP (1) EP1206281B1 (fr)
JP (1) JP5522877B2 (fr)
KR (1) KR100735788B1 (fr)
CN (1) CN1246039C (fr)
AR (1) AR025001A1 (fr)
AT (1) ATE270104T1 (fr)
AU (1) AU771058B2 (fr)
BG (1) BG65304B1 (fr)
BR (1) BRPI0013010B8 (fr)
CA (1) CA2378424C (fr)
CO (1) CO5190677A1 (fr)
CU (1) CU23367A3 (fr)
CZ (1) CZ298768B6 (fr)
DE (2) DE19937116A1 (fr)
DK (1) DK1206281T3 (fr)
EE (1) EE04771B1 (fr)
ES (1) ES2223549T3 (fr)
GT (1) GT200000123A (fr)
HK (1) HK1049615B (fr)
HN (1) HN2000000115A (fr)
HR (1) HRP20020198B1 (fr)
HU (1) HU229571B1 (fr)
IL (2) IL147553A0 (fr)
MA (1) MA25427A1 (fr)
MX (1) MXPA02001254A (fr)
MY (1) MY125356A (fr)
NO (1) NO320743B1 (fr)
NZ (1) NZ516969A (fr)
PE (1) PE20010400A1 (fr)
PL (1) PL198132B1 (fr)
PT (1) PT1206281E (fr)
RU (1) RU2260429C9 (fr)
SI (1) SI1206281T1 (fr)
SK (1) SK285650B6 (fr)
TW (1) TWI238719B (fr)
UA (1) UA72268C2 (fr)
UY (1) UY26269A1 (fr)
WO (1) WO2001010465A1 (fr)
ZA (1) ZA200200215B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE10218328A1 (de) 2002-03-05 2003-09-25 Humboldt Uni Zu Berlin Medizin Mittel zur präventiven Therapie nach akutem Schlaganfall
US20040197408A1 (en) * 2002-12-30 2004-10-07 Angiotech International Ag Amino acids in micelle preparation
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
DE102006031175A1 (de) * 2006-07-06 2008-01-10 Bayer Healthcare Ag Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur
US7537532B2 (en) * 2007-05-16 2009-05-26 Young Carl D Handle for implement and method
CN101787022B (zh) * 2009-10-09 2012-08-22 浙江医药股份有限公司新昌制药厂 一种喹啉羧酸盐酸盐一水合物晶型及其制备方法
WO2011086577A2 (fr) * 2010-01-12 2011-07-21 Msn Laboratories Limited Composition pharmaceutique de moxifloxacine et ses sels pharmaceutiquement acceptables
CN101836950A (zh) * 2010-03-12 2010-09-22 陕西合成药业有限公司 一种盐酸莫西沙星葡萄糖注射液及其制备方法和用途
CN103919779B (zh) * 2010-09-10 2016-02-10 杭州民生药业有限公司 一种含有莫西沙星的药物组合物
CN102100666B (zh) * 2011-01-17 2012-07-18 南京新港医药有限公司 一种新的盐酸莫西沙星注射剂
CN102093349B (zh) * 2011-01-17 2012-03-07 南京新港医药有限公司 一种工业化生产盐酸莫西沙星的方法
CN102688183B (zh) * 2011-03-21 2016-04-06 重庆医药工业研究院有限责任公司 一种稳定的盐酸莫西沙星注射剂
KR101435244B1 (ko) * 2011-04-12 2014-08-29 씨제이헬스케어 주식회사 목시플록사신 수성 제형 및 이의 제조방법
KR101327904B1 (ko) * 2011-08-16 2013-11-13 대한약품공업 주식회사 목시플록사신 염산염의 주사제형
RU2472507C1 (ru) * 2012-02-01 2013-01-20 Закрытое акционерное общество "Брынцалов-А" Водный состав на основе моксифлоксацина для парентерального введения
CN102600093B (zh) * 2012-04-11 2013-06-05 南京优科生物医药有限公司 一种莫西沙星片剂及其制备方法
GR1008168B (el) 2013-03-14 2014-04-08 "Φαρματεν Α.Β.Ε.Ε.", Παρεντερικο σκευασμα αντιβακτηριακου παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου
CN103191056B (zh) * 2013-04-28 2014-10-22 南京海融医药科技有限公司 莫西沙星的口服液体制剂及其制备方法和应用
WO2015093669A1 (fr) * 2013-12-20 2015-06-25 씨제이헬스케어 주식회사 Formulation aqueuse de moxifloxacine et sa méthode de préparation
CN103976944A (zh) * 2014-05-16 2014-08-13 成都青山利康药业有限公司 一种盐酸莫西沙星氯化钠注射液
CN104771359A (zh) * 2015-04-02 2015-07-15 南京正大天晴制药有限公司 一种稳定的盐酸莫西沙星注射液
CN105640876B (zh) * 2016-01-07 2019-04-12 天津红日药业股份有限公司 一种盐酸莫西沙星氯化钠注射液的制备工艺
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
EP3578182A1 (fr) * 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulations contenant des triazinones et du fer ayant une faible quantité d'ions de fer libres
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
CN111388415A (zh) * 2020-03-19 2020-07-10 石家庄四药有限公司 一种盐酸莫西沙星氯化钠注射液及其制备方法
EP4238552A1 (fr) 2020-10-29 2023-09-06 Taejoon Pharmaceutical Co., Ltd. Composition ophtalmique

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537761A1 (de) 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
JPH01258620A (ja) * 1988-04-08 1989-10-16 Dai Ichi Seiyaku Co Ltd 耳疾患用局所製剤
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
CA2053926A1 (fr) * 1989-04-28 1990-10-29 Genkichi Ohta Agent anti-vih
ES2102393T3 (es) 1989-12-29 1997-08-01 Abbott Lab Complejos de acido quinolona carboxilico--ion metalico--acido.
US5084276A (en) 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
FR2681863B1 (fr) 1991-09-27 1995-02-03 Rhone Dpc Europ Solution de sparfloxacine sa preparation et sel la constituant.
DE4306417A1 (de) * 1993-03-02 1994-09-08 Grace Gmbh Vorrichtung und Verfahren zum Verbrennen oxidierbarer Bestandteile in einem zu reinigenden Trägergas
CA2152828A1 (fr) * 1993-03-16 1994-07-07 Shin-Ichi Uesato Derives de l'acide 8-methoxyquinolonecarboxylique
KR960000223A (ko) 1994-06-08 1996-01-25 김정순 신규한 피리돈 카르복실산 화합물을 함유한 수용액 및 이의 제조방법
JP3416145B2 (ja) 1995-12-21 2003-06-16 ファイザー インク． 注射用キノロン製剤
JPH1192375A (ja) * 1997-09-25 1999-04-06 Morinaga Milk Ind Co Ltd ニューキノロン系抗菌剤の抗菌性を増強させる抗菌剤
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
EE04418B1 (et) * 1998-11-10 2005-02-15 Bayer Aktiengesellschaft Moksifloksatsiini farmatseutiline preparaat
DE19937115A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung

Also Published As

Publication number Publication date
UY26269A1 (es) 2001-03-16
DE50006974D1 (de) 2004-08-05
UA72268C2 (uk) 2005-02-15
ES2223549T3 (es) 2005-03-01
KR100735788B1 (ko) 2007-07-06
PT1206281E (pt) 2004-10-29
RU2260429C2 (ru) 2005-09-20
IL147553A (en) 2006-09-05
AR025001A1 (es) 2002-11-06
CU23367A3 (es) 2009-04-14
EE200200060A (et) 2003-04-15
RU2260429C9 (ru) 2006-03-27
KR20020022794A (ko) 2002-03-27
BG65304B1 (bg) 2008-01-31
CA2378424A1 (fr) 2001-02-15
BRPI0013010B8 (pt) 2021-05-25
CO5190677A1 (es) 2002-08-29
CN1368891A (zh) 2002-09-11
CZ298768B6 (cs) 2008-01-23
MXPA02001254A (es) 2002-08-12
HUP0203619A2 (hu) 2003-02-28
HUP0203619A3 (en) 2003-12-29
SK285650B6 (sk) 2007-05-03
MA25427A1 (fr) 2002-04-01
NO20020526D0 (no) 2002-02-01
AU6159600A (en) 2001-03-05
PL198132B1 (pl) 2008-05-30
TWI238719B (en) 2005-09-01
CA2378424C (fr) 2009-02-17
PL353405A1 (en) 2003-11-17
HK1049615B (zh) 2006-11-10
US6548079B1 (en) 2003-04-15
DE19937116A1 (de) 2001-02-08
HRP20020198A2 (en) 2004-02-29
GT200000123A (es) 2000-08-01
CZ2002458A3 (cs) 2002-06-12
SK1682002A3 (en) 2002-06-04
NO20020526L (no) 2002-02-01
HK1049615A1 (en) 2003-05-23
IL147553A0 (en) 2002-08-14
WO2001010465A1 (fr) 2001-02-15
BG106366A (en) 2002-08-30
NO320743B1 (no) 2006-01-23
BR0013010A (pt) 2002-04-30
EE04771B1 (et) 2007-02-15
ATE270104T1 (de) 2004-07-15
EP1206281B1 (fr) 2004-06-30
JP2003506416A (ja) 2003-02-18
HRP20020198B1 (en) 2011-02-28
AU771058B2 (en) 2004-03-11
MY125356A (en) 2006-07-31
BR0013010B1 (pt) 2013-12-10
JP5522877B2 (ja) 2014-06-18
ZA200200215B (en) 2002-09-25
HN2000000115A (es) 2001-02-02
EP1206281A1 (fr) 2002-05-22
SI1206281T1 (en) 2004-12-31
NZ516969A (en) 2004-03-26
CN1246039C (zh) 2006-03-22
HU229571B1 (en) 2014-02-28
PE20010400A1 (es) 2001-06-11

Similar Documents

Publication Publication Date Title
DK1206281T3 (da) Formulering indeholdende moxifloxacin og natriumchlorid
NO20021401D0 (no) Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
NO996440L (no) Omeprazol-natriumsalt
NO20013393D0 (no) Brönnsementeringsfremgangsmåter og sammensetninger
NO20022086D0 (no) Antidiabetisk formulering og fremgangsmåte
HUP0402236A3 (en) Heterocyclic compounds pharmaceutical compounds containing thereof and use thereof
IS2594B (is) Arýlmetýl-kabónýlamínó-þíasólafleiður og notkun þeirra sem æxlishemjandi efni
NO20022334L (no) Ny sammensetning og anvendelse
IS6411A (is) Kaspasa tálmar og notkun þeirra
NO20024099L (no) Lavdose entecavir-formulering og anvendelse
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
DK1057813T3 (da) Indolderivater og medicinske sammensætninger indeholdende de samme
NO20013318L (no) Substituerte 2-aryliminoheterocykliske forbindelser og preparater inneholdende disse for anvendelse
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
ID30032A (id) Formulasi farmasi
NO20001718D0 (no) Benzen-fusjonerte heterocykliske derivater og anvendelse derav
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
NO20013816L (no) Benzamidderivater og legemidler som inneholder disse
AR025867A1 (es) Formulacion portasdora farmaceutica